Clinical Trial Update: Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial is investigating a combination therapy of pembrolizumab, lenvatinib, and the IL-15 superagonist N-803 with a HER2-targeting autologous dendr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• AdHER2DC vaccine (HER2-targeting autologous dendritic cell vaccine (AdHER2DC))
• LENVIMA (lenvatinib)
• N-803
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Endometrial Cancer, Cancer of Endometrium | Phase 1, Phase 2 | Status: RECRUITING